Relmada Therapeutics (RLMD) News Today $0.29 +0.03 (+10.51%) Closing price 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.35%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comQ4 2024 Relmada Therapeutics Inc Earnings CallMarch 29, 2025 | uk.finance.yahoo.comRelmada Therapeutics reports Q4 EPS (62c) vs. (84c) last yearMarch 28, 2025 | markets.businessinsider.comRelmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone developmentMarch 28, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comRelmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateMarch 27, 2025 | globenewswire.com4RLMD : Insights Ahead: Relmada Therapeutics's Quarterly EarningsMarch 27, 2025 | benzinga.comRelmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025March 26, 2025 | globenewswire.comRelmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.March 25, 2025 | globenewswire.comRelmada acquires new Tourette syndrome treatment assetFebruary 6, 2025 | msn.comPsychedelic: Relmada acquires neurosteroid from AsarinaFebruary 6, 2025 | markets.businessinsider.comRelmada Therapeutics acquires Sepranolone from Asarina PharmaFebruary 6, 2025 | markets.businessinsider.comRelmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma ABFebruary 6, 2025 | globenewswire.comRLMD stock touches 52-week low at $0.34 amid sharp annual declineFebruary 3, 2025 | msn.comRelmada Therapeutics faces potential Nasdaq delistingJanuary 27, 2025 | msn.comRelmada To Discontinue REL-1017 Reliance II And Relight Phase 3 Trials; Mulls SaleDecember 10, 2024 | markets.businessinsider.comRelmada Therapeutics Shifts Focus After Study DiscontinuationDecember 10, 2024 | markets.businessinsider.comRelmada seeking strategic options after failed studyDecember 10, 2024 | seekingalpha.comRelmada seeking strategic options, stock climbs 5%December 10, 2024 | msn.comRelmada discontinues late-stage trials for depression drug, explores saleDecember 9, 2024 | reuters.comRelmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017December 9, 2024 | globenewswire.comMizuho Downgrades Relmada Therapeutics (RLMD)December 6, 2024 | msn.comMizuho Securities downgrades Relmada Therapeutics (RLMD) to a HoldDecember 5, 2024 | markets.businessinsider.comLeerink Partners Downgrades Relmada Therapeutics (RLMD)December 5, 2024 | msn.comRelmada reports DMC assessment indicates Phase 3 Reliance II trial is futileDecember 5, 2024 | finance.yahoo.comRelmada Therapeutics Stock Plummets Losing 80% Value - Here's WhyDecember 4, 2024 | benzinga.comRelmada Study of Major-Depression Treatment Deemed Futile; Shares Plummet - UpdateDecember 4, 2024 | marketwatch.comRelmada Therapeutics Study of Major Depressive Disorder Treatment Assessed as FutileDecember 4, 2024 | marketwatch.comRelmada's depression drug unlikely to meet main trial goal, analysis showsDecember 4, 2024 | reuters.comRelmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical SignificanceDecember 4, 2024 | globenewswire.comVestal Point Capital LP Has $1.59 Million Stake in Relmada Therapeutics, Inc. (NASDAQ:RLMD)Vestal Point Capital LP lowered its holdings in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) by 59.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 490,000 shares of the comNovember 29, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Stock Price Down 1.4% - Here's What HappenedRelmada Therapeutics (NASDAQ:RLMD) Trading Down 1.4% - Time to Sell?November 27, 2024 | marketbeat.comKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmNovember 21, 2024 | globenewswire.comRelmada Therapeutics to Present at Jefferies London Healthcare ConferenceNovember 20, 2024 | markets.businessinsider.comRelmada Therapeutics initiates Phase 1 dosing with REL-P11November 14, 2024 | markets.businessinsider.comRelmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic DiseaseNovember 14, 2024 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comRelmada Therapeutics: Strong Buy on Promising Pipeline and Financial StabilityNovember 11, 2024 | markets.businessinsider.comRelmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call TranscriptNovember 10, 2024 | seekingalpha.comRelmada Therapeutics Inc. Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | prnewswire.comRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comA Look Ahead: Relmada Therapeutics's Earnings ForecastNovember 6, 2024 | benzinga.comRelmada Therapeutics (RLMD) to Release Quarterly Earnings on ThursdayRelmada Therapeutics (NASDAQ:RLMD) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 5, 2024 | marketbeat.comRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024November 4, 2024 | globenewswire.comQ3 Earnings Estimate for RLMD Issued By Leerink PartnrsRelmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Analysts at Leerink Partnrs dropped their Q3 2024 earnings estimates for Relmada Therapeutics in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per sOctober 18, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Stock Quotes, Forecast and News SummaryOctober 14, 2024 | benzinga.comHow To Find The Insider Trades That Consistently Outperform The Market – Under The RadarOctober 10, 2024 | benzinga.comRelmada Therapeutics (NASDAQ:RLMD) Shares Down 0.3% - What's Next?Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 0.3% - Here's WhyOctober 9, 2024 | marketbeat.comJefferies Upgrades Relmada Therapeutics (RLMD)September 18, 2024 | msn.com Remove Ads Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Media Mentions By Week RLMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLMD News Sentiment▼1.890.92▲Average Medical News Sentiment RLMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLMD Articles This Week▼11▲RLMD Articles Average Week Remove Ads Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Karyopharm Therapeutics News Precision BioSciences News Atara Biotherapeutics News Spero Therapeutics News Connect Biopharma News Celularity News FibroBiologics News MiNK Therapeutics News Surrozen News Kezar Life Sciences News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLMD) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for May 7th. Because on that day, I believe we could see a $2 Trillion shock INTO the ma...Timothy Sykes | SponsoredThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLMD Stock Free RLMD Stock Alerts